Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note In Phase 2 for HPV-associated cancers under NCI CRADA: R/M cervical cancer in combination with pembrolizumab; two newly-diagnosed oropharyngeal cancer trials (with pembrolizumab, and with neoadjuvant chemotherapy).
Status note Phase 1b enrollment complete. FDA Fast Track designation and Orphan Drug Designation in AML; company seeking strategic partnership to advance the program.
Status note Phase 1 enrollment paused as part of Aug 2024 strategic prioritization.
Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.